Screener
Monopar Therapeutics MNPR Total Current Assets
Total Current Assets at other companies
Other financials
Where this comes from
Reported directly by Monopar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AssetsCurrent.
The source filing: Monopar Therapeutics’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 2:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001437749-26-016982
| Line item | March 31, 2026 | December 31, 2025* |
|---|---|---|
| Cash and cash equivalents | $52,544,263 | $61,833,552 |
| Investments | 84,948,677 | 78,565,491 |
| Other current assets | 250,903 | 63,745 |
| Total current assets | 137,743,843 | 140,462,788 |
| Operating lease right-of-use asset | 239,882 | 254,921 |
| Total assets | $137,983,725 | $140,717,709 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: |
Document
FAQ
- What is Monopar Therapeutics's total current assets?
- Monopar Therapeutics (MNPR) reported total current assets of $137.74M in Q1 2026.
- How has Monopar Therapeutics's total current assets changed year-over-year?
- Monopar Therapeutics's total current assets increased by 150.1% year-over-year, from $55.08M to $137.74M.
- What is the long-term trend for Monopar Therapeutics's total current assets?
- Over 5 years (2020 to 2025), Monopar Therapeutics's total current assets has grown at a 52.9% compound annual growth rate (CAGR), from $16.8M to $140.46M.
- What does total current assets mean?
- The sum of all assets expected to be converted to cash or consumed within one year — cash, receivables, inventory, and prepaid expenses.
Ask your AI about Monopar Therapeutics's total current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude